Search

Your search keyword '"Michitaka, Kojiro"' showing total 862 results
Start Over Author "Michitaka, Kojiro"
862 results on '"Michitaka, Kojiro"'

151. The Seroepidemiology of Hepatitis A and B in a Japanese Town

Author

Akbar, S.M. Fazle, Onji, Morikazu, Kanaoka, Mitso, Horiike, Norio, Michitaka, Kojiro, Masumoto, Toshikazu, Nonaka, Takashi, Kanda, Kimitoshi, Kajino, Kazunori, Kumamoto, Izumi, Nadano, Seijin, and Ohta, Yasuyuki

Published
1992

153. What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?

Author

Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Kariyama, Kazuya, Tani, Joji, Fukunishi, Shinya, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Kawata, Kazuhito, Yasuda, Satoshi, Toyoda, Hidenori, Ohama, Hideko, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Hayama, Korenobu, Arai, Taeang, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Michitaka, Kojiro, Hiasa, Yoichi, and Kudo, Masatoshi

Abstract

Background/Aim:An effective postprogression treatment of lenvatinib (LEN) against unresectable hepatocellular carcinoma (u-HCC) has not been established. We aimed to elucidate the clinical role of continuing LEN beyond progression of disease (PD). Methods:From March 2018 to October 2020, 99 u-HCC patients, in whom PD was confirmed (male:female = 78:21, median age 72 years, Child-Pugh A = 99, Barcelona Clinic Liver Cancer stage A:B:C = 2:43:54, LEN as first-line = 55), were enrolled (stopped LEN at PD [A group], n= 26; continued LEN beyond PD [B group], n= 73). Radiological response was evaluated with RECIST 1.1. Clinical features and prognostic factors for overall survival (OS) were retrospectively investigated using inverse probability weighting (IPW) calculated by propensity score. Results:Median time to progression, best response, and modified albumin-bilirubin grade (mALBI) at both baseline and PD did not show significant difference between the groups. Postprogression treatment in the A group was best supportive care in 17, sorafenib in 4, regorafenib in 3, ramucirumab in 1, and hepatic arterial infusion chemotherapy in 1. After adjusting with IPW, the B group showed better prognosis in regard to OS after PD and OS after introducing LEN than the A group (10.8/19.6 vs. 5.8/11.2 months, p< 0.001, respectively). In IPW-adjusted Cox hazard multivariate analysis, significant prognostic factors for OS after PD were mALBI 2b/3 at PD (HR 1.983, p= 0.021), decline of Eastern Cooperative Oncology Group performance status (ECOG PS) from baseline at PD (HR 3.180, p< 0.001), elevated alpha-fetoprotein (≥100 ng/mL) at introducing LEN (HR 2.511, p= 0.004), appearance of new extrahepatic metastasis (HR 2.396, p= 0.006), positive for hand-foot skin reaction (HFSR) before PD (any grade) (HR 0.292, p< 0.001), and continuing LEN beyond PD (HR 0.297, p< 0.001). Conclusion:When ECOG PS and hepatic reserve function permit, continuing LEN treatment beyond PD, especially in u-HCC patients showed HFSR during LEN treatment, might be a good therapeutic option, at least until a more effective drug as a postprogression treatment after LEN failure is developed.

Published
2021
Full Text
View/download PDF

154. Muscle volume loss a prognostic factor for death in liver cirrhosis patients and special relationship to portal hypertension

Author

Hiraoka, Atsushi, primary, Kitahata, Shogo, additional, Izumoto, Hirofumi, additional, Ueki, Hidetaro, additional, Aibiki, Toshihiko, additional, Okudaira, Tomonari, additional, Miyamoto, Yuji, additional, Yamago, Hiroka, additional, Iwasaki, Ryuichiro, additional, Tomida, Hideomi, additional, Mori, Kenichiro, additional, Kishida, Masato, additional, Tsubouchi, Eiji, additional, Miyata, Hideki, additional, Ninomiya, Tomoyuki, additional, Hirooka, Masashi, additional, Tokumoto, Yoshio, additional, Abe, Masanori, additional, Matsuura, Bunzo, additional, Hiasa, Yoichi, additional, and Michitaka, Kojiro, additional

Published
2017
Full Text
View/download PDF

155. Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis

Author

Toyoda, Hidenori, primary, Hiraoka, Atsushi, additional, Tada, Toshifumi, additional, Michitaka, Kojiro, additional, Takaguchi, Koichi, additional, Tsuji, Kunihiko, additional, Itobayashi, Ei, additional, Takizawa, Daichi, additional, Hirooka, Masashi, additional, Koizumi, Yohei, additional, Ochi, Hironori, additional, Joko, Koji, additional, Kisaka, Yoshiyasu, additional, Shimizu, Yuko, additional, Tajiri, Kazuto, additional, Tani, Joji, additional, Taniguchi, Tatsuya, additional, Toshimori, Akiko, additional, Fujioka, Shinichi, additional, and Kumada, Takashi, additional

Published
2017
Full Text
View/download PDF

156. Importance of Screening for Esophagogastric Varices in Naive Hepatocellular Carcinoma Patients Within Milan Criteria: Indicator for Liver Transplantation

Author

Kawakami, Takamasa, primary, Hiraoka, Atsushi, additional, Michitaka, Kojiro, additional, Kishida, Masato, additional, Ochi, Marie, additional, Kitahata, Shogo, additional, Ninomiya, Tomoyuki, additional, Hirooka, Masashi, additional, Matsuura, Bunzo, additional, and Hiasa, Yoichi, additional

Published
2017
Full Text
View/download PDF

157. Which Therapeutic Method Should be Selected in Non-Viral Hepatitis and Early Hepatocellular Carcinoma: Resection or Ablation? Multi-Center Analysis Using with Propensity Score Matching

Author

Kishida, Masato, primary, Hiraoka, Atsushi, additional, Kumada, Takashi, additional, Nouso, Kazuhiro, additional, Tsuji, Kunihiko, additional, Itobayashi, Ei, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Ishikawa, Toru, additional, Toyoda, Hidenori, additional, Tada, Toshifumi, additional, Matsuura, Bunzo, additional, Hiasa, Yoichi, additional, Ninomiya, Tomoyuki, additional, and Michitaka, Kojiro, additional

Published
2017
Full Text
View/download PDF

158. Proposal of High Risk Group for Hepatocellular Carcinoma in Japanese Patients with Diabetes Mellitus: Need for Extensive Surveillance with Ultrasonography

Author

Ochi, Marie, primary, Hiraoka, Atsushi, additional, Hirooka, Masashi, additional, Kitahata, Shogo, additional, Matsuura, Bunzo, additional, Hiasa, Yoichi, additional, Kishida, Masato, additional, Kawakami, Takamasa, additional, Ninomiya, Tomoyuki, additional, and Michitaka, Kojiro, additional

Published
2017
Full Text
View/download PDF

160. Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation

Author

Hiraoka, Atsushi, primary, Kumada, Takashi, additional, Michitaka, Kojiro, additional, Toyoda, Hidenori, additional, Tada, Toshifumi, additional, Takaguchi, Koichi, additional, Tsuji, Kunihiko, additional, Itobayashi, Ei, additional, Takizawa, Daichi, additional, Hirooka, Masashi, additional, Koizumi, Yohei, additional, Ochi, Hironori, additional, Joko, Koji, additional, Kisaka, Yoshiyasu, additional, Shimizu, Yuko, additional, Tajiri, Kazuto, additional, Tani, Joji, additional, Taniguchi, Tatsuya, additional, Toshimori, Akiko, additional, and Fujioka, Shinichi, additional

Published
2017
Full Text
View/download PDF

161. Simple method with tumor markers for predicting prognosis following transcatheter arterial chemo-embolization for switching to next therapy in intermediate hepatocellular carcinoma: multi-center analysis

Author

Hiraoka, Atsushi, primary, Kumada, Takashi, additional, Nouso, Kazuhiro, additional, Tsuji, Kunihiko, additional, Itobayashi, Ei, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Ishikawa, Toru, additional, Toyoda, Hidenori, additional, Tada, Toshifumi, additional, Hiasa, Yoichi, additional, and Michitaka, Kojiro, additional

Published
2017
Full Text
View/download PDF

162. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases

Author

Izumoto, Hirofumi, primary, Hiraoka, Atsushi, additional, Ishimaru, Yoshihiro, additional, Murakami, Tadashi, additional, Kitahata, Shogo, additional, Ueki, Hidetaro, additional, Aibiki, Toshihiko, additional, Okudaira, Tomonari, additional, Miyamoto, Yuji, additional, Yamago, Hiroka, additional, Iwasaki, Ryuichiro, additional, Tomida, Hideomi, additional, Mori, Kenichiro, additional, Kishida, Masato, additional, Tsubouchi, Eiji, additional, Miyata, Hideki, additional, Ninomiya, Tomoyuki, additional, Kawasaki, Hideki, additional, Hirooka, Masashi, additional, Matsuura, Bunzo, additional, Abe, Masanori, additional, Hiasa, Yoichi, additional, Michitaka, Kojiro, additional, and Kudo, Masatoshi, additional

Published
2017
Full Text
View/download PDF

163. An emergent case of hepatic aneurysms with internal cervical and middle cerebral aneurysms

Author

Ohta, Shogo, primary, Michitaka, Kojiro, additional, Suga, Yoshifumi, additional, Kaneto, Miho, additional, Ueki, Hidetaro, additional, Aibiki, Toshihiko, additional, Okudaira, Tomonari, additional, Kawakami, Takamasa, additional, Miyamoto, Yuji, additional, Yamago, Hiroka, additional, Tomida, Hideomi, additional, Mori, Kenichirou, additional, Hiraoka, Atsushi, additional, Ninomiya, Tomoyuki, additional, Kawaguchi, Naoto, additional, and Ishimaru, Yoshihiro, additional

Published
2017
Full Text
View/download PDF

164. A case of hepatocellular carcinoma with sarcomatous change treated with sorfenib

Author

Murakami, Taisei, primary, Hiraoka, Atsushi, additional, Ueki, Hidetaro, additional, Kaneto, Miho, additional, Kitahata, Shogo, additional, Okudaira, Tomonari, additional, Yamago, Hiroka, additional, Tomida, Hideomi, additional, Miyamoto, Yuji, additional, Iwasaki, Ryuichiro, additional, Suga, Yoshifumi, additional, Mori, Kenichiro, additional, Miyata, Hideki, additional, Kishida, Masato, additional, Ninomiya, Tomoyuki, additional, Kawasaki, Hideki, additional, Kito, Katsumi, additional, Hirooka, Masashi, additional, Hiasa, Yoichi, additional, and Michitaka, Kojiro, additional

Published
2017
Full Text
View/download PDF

166. Abdominal Ultrasound Findings of Tumor-Forming Hepatic Malignant Lymphoma

Author

Kitahata, Shogo, primary, Hiraoka, Atsushi, additional, Kudo, Masatoshi, additional, Murakami, Taisei, additional, Ochi, Marie, additional, Izumoto, Hirofumi, additional, Ueki, Hidetaro, additional, Kaneto, Miho, additional, Aibiki, Toshihiko, additional, Okudaira, Tomonari, additional, Yamago, Hiroka, additional, Miyamoto, Yuji, additional, Iwasaki, Ryuichiro, additional, Tomida, Hideomi, additional, Mori, Kenichiro, additional, Kishida, Masato, additional, Miyata, Hideki, additional, Tsubouchi, Eiji, additional, Hirooka, Masashi, additional, Koizumi, Yohei, additional, Ninomiya, Tomoyuki, additional, Hiasa, Yoichi, additional, and Michitaka, Kojiro, additional

Published
2017
Full Text
View/download PDF

167. Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib

Author

Hiraoka, Atsushi, Kumada, Takashi, Fukunishi, Shinya, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Kariyama, Kazuya, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Tada, Toshifumi, Toyoda, Hidenori, Yokohama, Keisuke, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Hayama, Korenobu, Arai, Taeang, Imai, Michitaka, Joko, Kouji, Koizumi, Yohei, Hiasa, Yoichi, Michitaka, Kojiro, and Kudo, Masatoshi

Abstract

Background/Aim:Post-progression treatment following tyrosine-kinase inhibitor (TKI) failure in patients with unresectable hepatocellular carcinoma (u-HCC) is important to prolong post-progression survival (PPS), which has a good correlation with overall survival (OS). This study aimed to elucidate the clinical features of progressive disease (PD) in patients treated with lenvatinib (LEN). Materials/Methods:From March 2018 to June 2019, 156 u-HCC patients with Child-Pugh A were enrolled (median age: 71 years, Child-Pugh score 5:6 = 105:51, BCLC A:B:C = 8:56:92, modified albumin-bilirubin grade (mALBI) 1:2a:2b = 59:42:55, past history of sorafenib:regorafenib = 57:17). Clinical features were retrospectively evaluated. Results:The median observation period was 8.5 months. Median OS was not obtained, while median time to decline to Child-Pugh B (CPB) was 11.4 months, median time to progression (TTP) was 8.4 months, and the period of LEN administration was 7.3 months. When we compared predictive values for time to decline to CPB based on Child-Pugh score and mALBI, values for Akaike information criterion (AIC) score and c-index of mALBI were superior as compared to Child-Pugh score (AIC: 592.3 vs. 599.7) (c-index: 0.655 vs. 0.597). Of the 73 patients with PD, 32 (43.8%) showed no decline to CPB or death. After excluding 3 without alpha-fetoprotein data at PD determination, only 14 (20.0%) of 70 showed REACH-2 eligibility. Non-mALBI 1/2a at the start of LEN was a significant risk factor for decline to CPB during LEN treatment (HR 2.552, 95% CI: 1.577–4.129; p< 0.001). Conclusion:Introduction of TKI therapy including LEN for u-HCC patients with better hepatic function (mALBI 1/2a: ALBI score ≤–2.27), when possible, increases the chance of undergoing post-progression treatment, which can improve PPS.

Published
2020
Full Text
View/download PDF

169. Prospective cohort trial to confirm the efficacy of no‐touch radio frequency ablation.

Author

Hirooka, Masashi, Hiraoka, Atsushi, Ochi, Hironori, Koizumi, Yohei, Michitaka, Kojiro, Joko, Kouji, Abe, Masanori, and Hiasa, Yoichi

Subjects
CATHETER ablation
Abstract

Background and Aim: The aim of the present prospective study was to evaluate tumor recurrence (intrasubsegmental recurrence‐free survival and local tumor recurrence‐free survival) and hepatic functional reserve following no‐touch ablation. Methods: The prospective cohort study protocols were approved by the institutional ethics committee. All patients provided written, informed consent. Between January 2014 and September 2016, 231 patients with 277 hepatocellular carcinoma nodules were prospectively enrolled. An internally cooled bipolar electrode was used for no‐touch ablation, while a monopolar electrode was used for direct puncture ablation. The intrasubsegmental recurrence‐free survival rate was the primary end‐point. The secondary outcomes were the local recurrence‐free survival rate, the disease‐free survival rate, and the changes in the Child–Pugh score. Results: No‐touch ablation resulted in significantly higher cumulative intrasubsegmental tumor recurrence‐free survival rates than direct puncture ablation (98.0% vs 87.1% at 1 year, 96.9% vs 76.8% at 2 years, and 91.0% vs 68.3% at 3 years, P < 0.001). The no‐touch group also showed significantly better local recurrence‐free survival and disease‐free survival. Even when only primary cases were analyzed, the same results were obtained. To adjust for differences in the background characteristics, inverse probability of treatment weighting adjustment was performed. Only intrasubsegmental tumor recurrence‐free survival was significantly better in the no‐touch group (hazard ratio [HR], 0.08; 95% confidence interval [CI], 0.02–0.20, P < 0.001); there was no difference in local tumor recurrence‐free survival (HR, 0.36; 95% CI, 0.10–1.02, P = 0.071). Conclusions: No‐touch ablation appears to be an ideal method for the prevention of intrahepatic dissemination. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

170. Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis.

Author

Hiraoka, Atsushi, Ochi, Marie, Murakami, Taisei, Izumoto, Hirofumi, Ueki, Hidetaro, Kitahata, Shogo, Aibiki, Toshihiko, Okudaira, Tomonari, Yamago, Hiroka, Iwasaki, Ryuichiro, Tomida, Hideomi, Miyamoto, Yuji, Mori, Kenichiro, Miyata, Hideki, Tsubouchi, Eiji, Kishida, Masato, Ninomiya, Tomoyuki, Michitaka, Kojiro, Kumada, Takashi, and Toyoda, Hidenori

Subjects
ANTIVIRAL agents, HEPATOCELLULAR carcinoma, HEPATITIS C virus, DISEASE risk factors
Abstract

Background and Aim: To develop a scoring method using with common clinical data for predicting hepatocellular carcinoma (HCC) development after sustained virological response at 24 weeks (SVR24) after treatment with direct acting antivirals (DAAs), we retrospectively evaluated clinical features of patients who obtained SVR24. Methods: From October 2014 to December 2017, 1069 hepatitis C virus patients without a past history of HCC, who obtained SVR24 by DAAs at two different areas, were enrolled (the training [n = 484, ChuShikoku‐group] and validation [n = 585, Chubu‐group] sets). All were examined by ultrasonography as surveillance for HCC at the time of starting DAAs and twice a year after SVR24. We identified three parameters at SVR24, male gender, FIB‐4 index > 3.25, and α‐fetoprotein level > 5.0 ng/mL, as risk factors for HCC development and gave them point values, with the sum used as After DAAs Recommendation for Surveillance (ADRES) score. Results: In the ChuShikoku‐group, the respective 1‐/2‐year rates for HCC incidence rates ADRES score 0 were 0.0%/0.0%, for a score 1 were 1.1%/2.1%, score 2 were 8.8%/15.9%, and score 3 were 17.1%/28.1%. On the other hand, those respective scores for the Chubu‐group were 0.0%/0.0%, 0.0%/0.7%, 7.9%/10.6%, and 19.5%/not available. The c‐index of the predictive value for HCC development in the training set after SVR24 was 0.835 while 0.899 in the validation set. Finally, those of the entire cohort were 0.0%/0.0%, 0.5%/1.6%, 8.4%/13.4%, and 18.0%/32.8%. Conclusion: The present ADRES score was simple and easy to use and may be useful for predicting risk of HCC development in short term after reaching SVR24 by DAAs. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

171. Predictors of hepatocellular carcinoma occurrence after direct‐acting antiviral therapy in patients with hepatitis C virus infection.

Author

Watanabe, Takao, Tokumoto, Yoshio, Joko, Kouji, Michitaka, Kojiro, Horiike, Norio, Tanaka, Yoshinori, Tada, Fujimasa, Kisaka, Yoshiyasu, Nakanishi, Seiji, Yamauchi, Kazuhiko, Yukimoto, Atsushi, Hirooka, Masashi, Abe, Masanori, and Hiasa, Yoichi

Subjects
HEPATITIS C virus, HEPATITIS C, VIRUS diseases, LIVER cancer, MULTIVARIATE analysis, CONFIDENCE intervals
Abstract

Aim: The predictors for the development of hepatocellular carcinoma (HCC) after direct‐acting antiviral (DAA) treatment were investigated. Methods: A total of 1174 patients with chronic hepatitis C virus infection were treated with DAA therapy (sofosbuvir and ledipasvir [n = 615], sofosbuvir and ribavirin [n = 380], and daclatasvir and asunaprevir [n = 179]) and achieved sustained virologic response (SVR). The HCC development rate and the factors that might contribute to the development of HCC after the end of DAA treatment were analyzed. Results: During the median observation period of 537 days, HCC developed in 33 cases. The incidence of HCC was 1.9%, 3.2%, and 4.1% at 1, 1.5, and 2 years after the end of DAA therapy, respectively. Multivariate analysis with pre‐ and post‐treatment factors identified the Fibrosis‐4 (FIB‐4) index (hazard ratio [HR] = 1.09; 95% confidence interval [CI], 1.021–1.178; P = 0.011) and post‐treatment α‐fetoprotein (AFP) (HR = 1.11; 95% CI, 1.054–1.172; P < 0.001) as independent factors that contributed to the development of HCC after DAA therapy. Using these identified parameters, a new scoring system (0 to 2 points) was established. Patients in the high‐score group (2 points) could be identified as having a significantly higher risk of HCC development, and the respective 1‐ and 2‐year cumulative incidence rates of HCC were 6.1% and 14.4%. Conclusions: A high FIB‐4 index and a high post‐treatment AFP at the end of DAA treatment were the independent predictors for developing HCC after DAA treatment. For patients with these risk factors, extra attention to the possibility of HCC development is needed. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

173. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis.

Author

Hiraoka, Atsushi, Kumada, Takashi, Kariyama, Kazuya, Takaguchi, Koichi, Itobayashi, Ei, Shimada, Noritomo, Tajiri, Kazuto, Tsuji, Kunihiko, Ishikawa, Toru, Ochi, Hironori, Hirooka, Masashi, Tsutsui, Akemi, Shibata, Hiroshi, Tada, Toshifumi, Toyoda, Hidenori, Nouso, Kazuhiro, Joko, Kouji, Hiasa, Yoichi, and Michitaka, Kojiro

Subjects
RUBELLA, LIVER cancer, CANCER treatment
Abstract

Aim: Lenvatinib (LEN) has recently become available as a first‐line tyrosine‐kinase inhibitor (TKI) for unresectable hepatocellular carcinoma (u‐HCC). In patients who showed intolerability or failure in other TKI treatments, alternative treatment options are needed. This retrospective study evaluated the therapeutic potential of LEN in clinical practice. Methods: We enrolled 57 u‐HCC patients treated with LEN from March to June 2018. Lenvatinib was given orally to patients weighing <60 kg at 8 mg/day and at 12 mg/day to those ≥60 kg. Following the exclusion of patients whose initial LEN dose was reduced, 49 patients were evaluated in regard to their characteristics and early therapeutic response using modified Response Evaluation Criteria in Solid Tumors for findings of follow‐up computed tomography (CT)/magnetic resonance imaging (MRI) examinations at 4 weeks after introducing LEN. Results: The average patient age was 72.4 ± 9.3 years and 38 (77.6%) were men. The LEN dose was 8 and 12 mg in 32 and 17 patients, respectively. Twenty‐nine (59.2%) had history of treatment with sorafenib and six of them (20.7%) with regorafenib. Of the 49 patients, 27 were evaluated using findings obtained by enhanced CT/MRI at 4 weeks after introducing LEN. Partial response was shown in 11, stable disease in 12, and progressive disease in four (overall response rate [ORR], 40.7%; disease control rate [DCR], 85.2%). The ORR and DCR of TKI‐naïve patients (n = 8) were 50.0% and 87.5%, respectively, whereas those of TKI‐experienced patients (n = 19) were 36.8% and 84.2%, respectively (P = 0.675 and P = 1.00, respectively). Conclusion: Early therapeutic response to LEN was favorable. This new TKI could have therapeutic potential both in patients with and without past TKI treatments. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

175. Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib

Author

Hiraoka, Atsushi, primary, Hirooka, Masashi, additional, Koizumi, Yohei, additional, Izumoto, Hirofumi, additional, Ueki, Hidetaro, additional, Kaneto, Miho, additional, Kitahata, Shogo, additional, Aibiki, Toshihiko, additional, Tomida, Hideomi, additional, Miyamoto, Yuji, additional, Yamago, Hiroka, additional, Suga, Yoshifumi, additional, Iwasaki, Ryuichiro, additional, Mori, Kenichiro, additional, Miyata, Hideki, additional, Tsubouchi, Eiji, additional, Kishida, Masato, additional, Ninomiya, Tomoyuki, additional, Abe, Masanori, additional, Matsuura, Bunzo, additional, Kawasaki, Hideki, additional, Hiasa, Yoichi, additional, and Michitaka, Kojiro, additional

Published
2016
Full Text
View/download PDF

177. Sarcopenia and two types of presarcopenia in Japanese patients with chronic liver disease

Author

Hiraoka, Atsushi, primary, Michitaka, Kojiro, additional, Ueki, Hidetaro, additional, Kaneto, Miho, additional, Aibiki, Toshihiko, additional, Okudaira, Tomonari, additional, Kawakami, Takamasa, additional, Yamago, Hiroka, additional, Suga, Yoshifumi, additional, Tomida, Hideomi, additional, Miyamoto, Yuji, additional, Azemoto, Nobuaki, additional, Mori, Kenichiro, additional, Miyata, Hideki, additional, Tsubouchi, Eiji, additional, Ninomiya, Tomoyuki, additional, Hirooka, Masashi, additional, Abe, Masanori, additional, Matsuura, Bunzo, additional, and Hiasa, Yoichi, additional

Published
2016
Full Text
View/download PDF

179. Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients

Author

Watanabe, Takao, primary, Joko, Kouji, additional, Seike, Hirotaka, additional, Michitaka, Kojiro, additional, Horiike, Norio, additional, Kisaka, Yoshiyasu, additional, Tanaka, Yoshinori, additional, Nakanishi, Seiji, additional, Nakanishi, Kimio, additional, Nonaka, Takashi, additional, Yamauchi, Kazuhiko, additional, Onji, Morikazu, additional, Ohno, Yoshinori, additional, Tokumoto, Yoshio, additional, Hirooka, Masashi, additional, Abe, Masanori, additional, and Hiasa, Yoichi, additional

Published
2016
Full Text
View/download PDF

181. Su1470 Curative Treatments of Hemodialysis Patients With Hepatocellular Carcinoma: Comparison Between Resection and Radiofrequency Ablation

Author

Hiraoka, Atsushi, primary, Kumada, Takashi, additional, Ueki, Hidetaro, additional, Tada, Toshifumi, additional, Toyoda, Hidenori, additional, Koizumi, Yohei, additional, Hirooka, Masashi, additional, Ninomiya, Tomoyuki, additional, Abe, Masanori, additional, Matsuura, Bunzo, additional, Hiasa, Yoichi, additional, Taniguchi, Tatsuya, additional, Itobayashi, Ei, additional, Tajiri, Kazuto, additional, Fujioka, Shin-ichi, additional, Ochi, Hironori, additional, Joko, Kouji, additional, Tsuji, Kunihiko, additional, Kisaka, Yoshiyasu, additional, Shimizu, Yuko, additional, Takizawa, Daichi, additional, Toshimori, Akiko, additional, Tani, Joji, additional, Azemoto, Nobuaki, additional, and Michitaka, Kojiro, additional

Published
2016
Full Text
View/download PDF

182. Prognostic Scoring System for radiofrequency ablation: Usefulness of Albumin-bilirubin (ALBI)-grade

Author

Hiraoka, Atsushi, primary, Kumada, Takashi, additional, Itobayashi, Ei, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Nouso, Kazuhiro, additional, Tada, Toshifumi, additional, Toyoda, Hidenori, additional, Hiasa, Yoichi, additional, and Michitaka, Kojiro, additional

Published
2016
Full Text
View/download PDF

183. High fever and arrhythmia that emerged after drinking alcohol in a patient with chronic hepatitis C under treatment with ledipasvir/sofosbuvir

Author

Hukuoka, Kanako, primary, Michitaka, Kojiro, additional, Tsubouchi, Eiji, additional, Kanetoh, Miho, additional, Aibiki, Toshihiko, additional, Okudaira, Tomonari, additional, Yamago, Hiroka, additional, Miyamoto, Yuji, additional, Tomida, Hideomi, additional, Suga, Yosihumi, additional, Mori, Kenichiro, additional, Hiraoka, Atsushi, additional, and Ninomiya, Tomoyuki, additional

Published
2016
Full Text
View/download PDF

184. A Possible Case of Hepatitis due to Hypereosinophilic Syndrome

Author

Kawamura, Tomoe, primary, Hiraoka, Atsushi, additional, Toshimori, Akiko, additional, Ueki, Hidetaro, additional, Kaneto, Miho, additional, Aibiki, Toshihiko, additional, Okudaira, Tomonari, additional, Yamago, Hiroka, additional, Nakahara, Hiromasa, additional, Tomida, Hideomi, additional, Suga, Yoshifumi, additional, Azemoto, Nobuaki, additional, Mori, Kenichiro, additional, Miyata, Hideki, additional, Ninomiya, Tomoyuki, additional, Hirooka, Masashi, additional, Abe, Masanori, additional, Matsuura, Bunzo, additional, Hiasa, Yoichi, additional, Kito, Katsumi, additional, and Michitaka, Kojiro, additional

Published
2016
Full Text
View/download PDF

185. Resected intrahepatic cholangiocellular sarcoma: case report and review of literature

Author

Toshimori, Akiko, primary, Hiraoka, Atsushi, additional, Asagi, Akinori, additional, Nakanishi, Kimio, additional, Ueki, Hidetaro, additional, Kaneto, Miho, additional, Aibiki, Toshihiko, additional, Okudaira, Tomonari, additional, Miyamoto, Yuji, additional, Tomita, Hideomi, additional, Yamago, Hiroka, additional, Suga, Yoshifumi, additional, Azemoto, Nobuaki, additional, Miyata, Hideki, additional, Tsubouchi, Eiji, additional, Ninomiya, Tomoyuki, additional, Kawasaki, Hideki, additional, Maeda, Toshiharu, additional, and Michitaka, Kojiro, additional

Published
2016
Full Text
View/download PDF

186. A case of unilocular serous cystadenoma in which preoperative diagnosis was difficult

Author

SHINE, Mikiya, primary, AZEMOTO, Nobuaki, additional, MIYATA, Hideki, additional, UEKI, Hidetaro, additional, KANETO, Miho, additional, AIBIKI, Toshihiko, additional, OKUDAIRA, Tomonari, additional, KAWAKAMI, Takamasa, additional, TOMIDA, Hideomi, additional, MIYAMOTO, Yuji, additional, YAMAGO, Hiroka, additional, SUGA, Yoshifumi, additional, MORI, Kenichiro, additional, HIRAOKA, Atsushi, additional, TSUBOUCHI, Eiji, additional, NINOMIYA, Tomoyuki, additional, MICHITAKA, Kojiro, additional, FUJII, Masahiko, additional, KAWASAKI, Hideki, additional, and SUGITA, Keiro, additional

Published
2016
Full Text
View/download PDF

187. A case of well-differentiated hepatocellular carcinoma complicated with bleeding in the tumor

Author

Kaneto, Miho, primary, Hiraoka, Atsushi, additional, Aibiki, Toshihiko, additional, Okudaira, Tomonari, additional, Kawamura, Tomoe, additional, Yamago, Hiroka, additional, Suga, Yoshifumi, additional, Azemoto, Nobuaki, additional, Mori, Kenichiro, additional, Ninomiya, Tomoyuki, additional, Kawasaki, Hideki, additional, Tokumoto, Yoshio, additional, Hiasa, Yoichi, additional, and Michitaka, Kojiro, additional

Published
2016
Full Text
View/download PDF

188. Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade

Author

Hiraoka, Atsushi, primary, Kumada, Takashi, additional, Nouso, Kazuhiro, additional, Tsuji, Kunihiko, additional, Itobayashi, Ei, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Ishikawa, Toru, additional, Tada, Toshifumi, additional, Toyoda, Hidenori, additional, Kawasaki, Hideki, additional, Hiasa, Yoichi, additional, and Michitaka, Kojiro, additional

Published
2016
Full Text
View/download PDF

189. A resected hepatic neuroendocrine carcinoma with elevation of AFP and fucosylated AFP

Author

Onishi, Kei, primary, Hiraoka, Atsushi, additional, Ueki, Hidetaro, additional, Kaneto, Miho, additional, Aibiki, Toshihiko, additional, Okudaira, Tomonari, additional, Kawakami, Takamasa, additional, Yamago, Hiroka, additional, Tomida, Hideomi, additional, Miyamoto, Yuji, additional, Suga, Yoshifumi, additional, Azemoto, Nobuaki, additional, Mori, Kenichiro, additional, Tsubouchi, Eiji, additional, Miyata, Hideki, additional, Ninomiya, Tomoyuki, additional, Sugita, Atsuro, additional, Kawasaki, Hideki, additional, and Michitaka, Kojiro, additional

Published
2016
Full Text
View/download PDF

192. Abstracts of selected papers presented at the 29th annual meeting of the Japanese society of gastroenterology Kofu, Japan, November 5–7, 1987

Author

Imai, Yasuharu, Kiyosawa, Kendo, Sata, Michio, Tanikawa, Kyuichi, Hino, Keisuke, Konishi, Tomomi, Tajima, Heiichiro, Yano, Michitami, Kojima, Toyoo, Ichida, Fumihiro, Ito, Tetsuo, Watanabe, Shozo, Tozuka, Shinichi, Uchida, Toshikazu, Michitaka, Kojiro, Ohta, Yasuyuki, Matsuura, Kazuharu, Tsuji, Takao, Shibayama, Takao, Tanaka, Satoshi, Shimizu, Masaru, Kojima, Mineo, Akahane, Yoshihiro, Miyazaki, Yoshiki, Kurai, Kiyohiko, Uno, Shiro, Yokosuka, Osamu, Omata, Masao, Hayashi, Norio, Kamada, Takenobu, Mizokami, Masashi, Orito, Etsuro, Tokita, Hajime, Kametani, Masaaki, Suga, Mitsuo, Yokota, Katsuji, Saito, Yasuharu, Higuchi, Akihiko, Sasaki, Yutaka, Hayashi, Norio, Fujimoto, Kazuma, Sakata, Toshiie, Naruse, S., Takagi, T., Tangoku, Akira, Ozasa, Hiroaki, Chiba, Tsutomu, Yamada, Tadataka, Azuma, Takeshi, Nakajima, Chiharu, Tada, Masahiro, Kawano, Hirofumi, Takayama, Sumio, Aoki, Teruaki, Kusano, Motoyasu, Nishioka, Toshio, Sakamoto, Tsuguo, Miyata, Masahiko, Iishi, Hiroyasu, Tatsuta, Masaharu, Okuno, Masaru, Himeno, Seiichi, Kobayashi, Masayoshi, Goto, Yoshio, Masuzawa, Shigeyuki, Tsuchita, Shuji, Ueno, Takato, Tanikawa, Kyuichi, Fukuda, Yoshihide, Nagura, Hiroshi, Tanaka, Yousuke, Manabe, Tadao, Fujimura, Masaki, Sakamoto, Tuguo, Funakoshi, Akihiro, Miyazaki, Kazunori, Sumi, Shoichiro, Inoue, Kazutomo, Ohshima, Ikuya, Kouzu, Teruo, Hashimoto, Hiroshi, Mitsunaga, Atsushi, Yasuda, Kenjiro, Nakajima, Masatsugu, Aibe, Tsuyoshi, Noguchi, Takayoshi, Yamanaka, Toshihiro, Nakamura, Tsuneya, Saitoh, Norio, Sarashina, Hiromi, Endoh, Masaaki, Konn, Mitsuru, Morita, Keiichi, Kanoh, Junichi, Abe, Minoru, Narisawa, Rintaro, Yamanaka, Takeo, Kimura, Ken, Kimura, Osamu, Korenaga, Daisuke, Hirose, Kazuo, Yonemura, Yutaka, Yoshino, Hiroaki, Akiyama, Toshio, Nakamura, Masahiro, Makiyama, Takao, Kosaka, Takeo, Masaki, Tadahiko, Omata, Kosaku, Une, Yoshie, Imai, Takazumi, Kagawa, Keizo, Hino, Akitsugu, Tarao, Kazuo, Kusano, Mitsuo, Tsugita, Masashi, Takahashi, Yutaka, Sujino, Hajime, and Tomino, Yoshiro

Published
1988
Full Text
View/download PDF

193. Hepatitis B Virus Reactivation Induced by Infliximab Administration in a Patient with Crohn’s Disease

Author

Miyake, Yuka, Hasebe, Aki, Tanihira, Tetsuya, Shiraishi, Akiko, Imai, Yusuke, Tatsukawa, Haruka, Yamago, Hiroka, Nakahara, Hiromasa, Shimizu, Yuko, Ninomiya, Keiko, Hiraoka, Atsushi, Miyata, Hideki, Ninomiya, Tomoyuki, and Michitaka, Kojiro

Subjects
Article Subject, virus diseases, digestive system diseases
Abstract

A 47-year-old man diagnosed with Crohn’s disease was treated with infliximab. He tested negative for hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) but positive for anti-HB core antibody (anti-HBc). He tested positive for hepatitis B virus (HBV-) DNA 3 months after treatment and was administered entecavir. HBV-DNA test showed negative results 1 month later. ALT was persistently within the normal range, and HBV-DNA was persistently negative thereafter despite the continuation of infliximab every 8 weeks. In our hospital, 14 patients with inflammatory bowel disease, who tested negative for HBsAg, were treated with infliximab; 2 of them tested positive for anti-HBs and/or anti-HBc, and HBV reactivation was observed in 1 patient (the present patient). The present case and these findings highlight that careful follow-up is needed in patients with inflammatory bowel disease treated with infliximab who test positive for anti-HBc and/or anti-HBs.

Published
2013
Full Text
View/download PDF

194. Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients

Author

Hiraoka, Atsushi, Kumada, Takashi, Michitaka, Kojiro, and Kudo, Masatoshi

Abstract

Background:Because of the rapid progression of antiviral treatment options and the increasing frequency of nonviral-related hepatocellular carcinoma (HCC) due to the aging of society, the number of HCC patients with good hepatic function has been increasing and a more detailed method of assessment of hepatic function is needed. The Child-Pugh classification (CP) is used worldwide as an assessment tool for hepatic reserve function, even though it has some weaknesses. Recently, the albumin-bilirubin (ALBI) grade, calculated based on only albumin and total bilirubin, was proposed, and recent investigations have suggested that ALBI grade instead of CP can be used as an assessment tool for hepatic function as part of therapeutic strategies such as Barcelona Clinic Liver Cancer staging and a practical guideline presented by the Japan Society of Hepatology as well for total staging scoring systems. There has been an increasing number of reports showing that it has better capability than CP for HCC patients who undergo not only curative but also palliative treatments. Transcatheter arterial chemoembolization (TACE) is a major palliative treatment used for unresectable HCC, and the idea of TACE-refractory status has been proposed to indicate the possibility of switching to a tyrosine kinase inhibitor (TKI). However, TKI administration requires a maintained hepatic reserve function, thus the importance of assessment of hepatic function in patients undergoing TACE treatments has increased. We consider that ALBI grade might also play a significant role as part of a detailed assessment of relative changes in hepatic function during treatment. In this review, we evaluate the practical usefulness of ALBI grade for assessing hepatic function and HCC prognosis. Key Message:A detailed assessment of hepatic function is required for recent HCC therapeutic strategies. ALBI grade may be a powerful tool to improve treatment options for affected patients.

Published
2019
Full Text
View/download PDF

195. Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan

Author

Hiraoka, Atsushi, Michitaka, Kojiro, Kumada, Takashi, Izumi, Namiki, Kadoya, Masumi, Kokudo, Norihiro, Kubo, Shoji, Matsuyama, Yutaka, Nakashima, Osamu, Sakamoto, Michiie, Takayama, Tadatoshi, Kokudo, Takashi, Kashiwabara, Kosuke, Eguchi, Susumu, Yamashita, Tatsuya, and Kudo, Masatoshi

Abstract

Background/Aim:Adequate assessment of transcatheter arterial chemoembolization (TACE)-refractory status has become more important for switching treatment in intermediate-stage (BCLC-B) hepatocellular carcinoma (HCC) patients treated with TACE. The usefulness of a previously proposed tumor marker score for predicting prognosis of BCLC-B HCC patients treated with TACE was investigated. Methods:Using a nationwide database, we examined the records of 1,306 naïve BCLC-B HCC with Child-Pugh A who were treated from 2001 to 2007, after excluding those with missing data (hepatic function or tumor markers) or cases with a single large tumor. Alpha-fetoprotein (AFP) ≥100 ng/mL, fucosylated AFP (AFP-L3) ≥10%, and des-gamma-carboxy prothrombin ≥100 mAU/mL were markers used to define positive cases. The number of positive tumor markers was used as a prognostic score, and its predictive value was evaluated in a retrospective manner. Results:Median survival time became shorter along with increased score (0, 1, ≥2 = 4.8, 3.8, 3.2 years, respectively; p< 0.01). Tumor marker score (≥2; hazard ratio [HR] 1.675, 95% confidence interval [CI] 1.372–2.044, p< 0.001), serum levels of albumin (≥3.5 g/dL; HR 0.726, 95% CI 0.528–0.997, p= 0.048), and up-to-7 criteria (HR 1.673, 95% CI 1.400–2.000, p< 0.001) were significant prognostic factors for death in the Cox hazard multivariate analysis. Conclusion:Tumor marker score had a useful predictive prognostic value in BCLC-B HCC treated with TACE. Especially in patients with a tumor marker score of 2 or greater, a poor therapeutic response should be expected, and appropriate judgement of TACE-refractory status is necessary.

Published
2019
Full Text
View/download PDF

196. Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis

Author

Hiraoka, Atsushi, Kumada, Takashi, Tsuji, Kunihiko, Takaguchi, Koichi, Itobayashi, Ei, Kariyama, Kazuya, Ochi, Hironori, Tajiri, Kazuto, Hirooka, Masashi, Shimada, Noritomo, Ishikawa, Toru, Tachi, Yoshihiko, Tada, Toshifumi, Toyoda, Hidenori, Nouso, Kazuhiro, Joko, Kouji, Hiasa, Yoichi, Michitaka, Kojiro, and Kudo, Masatoshi

Abstract

Background/Aim:The frequency of hepatocellular carcinoma (HCC) in patients with good hepatic reserve function has been increasing in Japan along with the progression of antiviral therapies and aging of the society. We evaluated the usefulness of modified albumin-bilirubin (ALBI) grade as a tool for assessment of hepatic reserve function. Materials/Methods:We enrolled 6,649 naïve HCC patients treated from 2000 to 2017 and divided them into training (Ehime Prefecture group: E group, n= 2,357) and validation (validation group: V group, n= 4,292) cohorts. Child-Pugh classification and ALBI and modified ALBI (mALBI) grading were compared using with Japan Integrated Staging (JIS), ALBI-TNM (ALBI-T), and mALBI-T scores, which were calculated based on TNM stage and each assessment tool, retrospectively. Results:In the E group, Akaike’s Information Criterion (AIC) and c-index values for mALBI-T (13,725.2/0.744) were better as compared to those of ALBI-T (13,772.6/0.733) and JIS score (13,874.7/0.720), with similar results observed in the V group (mALBI-T: 27,727.4/0.760; ALBI-T: 27,817.8/0.750; JIS: 27,807.5/0.748). Although there were some significant differences between the groups with regard to clinical background factors (age, etiology, tumor size, tumor number, treatment modalities), for all patients the AIC and c-index values of mALBI-T (45,327.1/0.755) were also better than those of ALBI-T (45,467.7/0.744) and JIS scores (45,555.8/0.739), indicating its superior stratification ability and prognostic predictive value in patients with HCC. Conclusion:The detailed stratification ability of mALBI grade for hepatic reserve function is suitable for the recent trend of HCC patients, while mALBI-T may provide a more accurate predictive value than existing total staging scoring systems.

Published
2019
Full Text
View/download PDF

197. Ultrasonography screening for hepatocellular carcinoma in Japanese patients with diabetes mellitus

Author

Hiraoka, Atsushi, primary, Ochi, Marie, additional, Matsuda, Rie, additional, Aibiki, Toshihiko, additional, Okudaira, Tomonari, additional, Kawamura, Tomoe, additional, Yamago, Hiroka, additional, Nakahara, Hiromasa, additional, Suga, Yoshifumi, additional, Azemoto, Nobuaki, additional, Miyata, Hideki, additional, Miyamoto, Yasunao, additional, Ninomiya, Tomoyuki, additional, Hirooka, Masashi, additional, Abe, Masanori, additional, Matsuura, Bunzo, additional, Hiasa, Yoichi, additional, and Michitaka, Kojiro, additional

Published
2015
Full Text
View/download PDF

198. Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients

Author

Watanabe, Takao, primary, Tokumoto, Yoshio, additional, Joko, Kouji, additional, Michitaka, Kojiro, additional, Mashiba, Toshie, additional, Hiraoka, Atsushi, additional, Ochi, Hironori, additional, Koizumi, Yohei, additional, Tada, Fujimasa, additional, Hirooka, Masashi, additional, Yoshida, Osamu, additional, Imai, Yusuke, additional, Abe, Masanori, additional, and Hiasa, Yoichi, additional

Published
2015
Full Text
View/download PDF

200. A case of hepatic angiosarcoma treated with paclitaxel

Author

Kanno, Yukari, primary, Hiraoka, Atsushi, additional, Aibiki, Toshihiko, additional, Okudaira, Tomonari, additional, Kawamura, Tomoe, additional, Yamago, Hiroka, additional, Nakahara, Hiromasa, additional, Suga, Yoshifumi, additional, Azemoto, Nobuaki, additional, Miyamoto, Yasunao, additional, Ninomiya, Tomoyuki, additional, and Michitaka, Kojiro, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results